Recruitment

First Opinion Jennifer Dent

Patients of African descent are being denied the benefits of cancer breakthroughs. We’re changing that

Biotech Kate Sheridan

Want to operate in China’s biotech scene? Here are five tips

Health Ike Swetlitz

African-Americans are disproportionately enrolled in studies that don’t require informed consent

Special Report Caroline Chen and Riley Wong — ProPublica

Denied ‘life-extending opportunities’: Black patients are being left out of clinical trials amid wave of new cancer therapies

Business Rebecca Robbins

With big-name backing, a startup launches to match cancer patients with clinical trials

Biotech Rebecca Robbins

Stock, sky-high salaries and a $10,000 watch: Startups desperately compete for top experts in gene and cell therapy

Business Rebecca Robbins

Powerful people in health care are finding a new landing pad: Google

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

First Opinion Mason Marks and Tiffany Li

DNA donors must demand stronger protection for genetic privacy

First Opinion Helen Torley

Diversity in the biopharma industry makes dollars and sense

In the Lab Elizabeth Cooney

Researchers mine emergency contacts to discover genetic clues to disease

Biotech Jonathan Saltzman — Boston Globe

The growth of Mass. biotechs is outpacing the number of qualified workers

First Opinion Melissa Burstein

More female leaders will help drive innovation in the medtech and biotech industries

First Opinion Jonathan Kimmelman and Alex John London

Cancer centers sell out science when they advertise clinical trials as treatment

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Health Rebecca Robbins

How a society gala was used to sell young-blood transfusions to baby boomers desperate to cheat death

First Opinion Andy Coravos and Sofia Warner

recruitment

Most Read

Listen: Pharma companies market their drugs to young adults — so why don’t they include them in clinical trials?

It’s all in the details: start-up packages and ongoing gender bias in academic medicine

Patient engagement: The true benchmark in clinical trials

Clinical trial sites face challenges in diversifying personnel and participants, study finds

Paying participants isn’t the way to improve clinical trial recruitment

How to rebrand a research study? For one project, Instagram influencers and a dash of wit go a long way

How to create successful leadership teams for cell and gene therapy companies

Tempus, a well-funded company run by a Groupon billionaire, wants to get patients into clinical trials

All Coverage

Patients of African descent are being denied the benefits of cancer breakthroughs. We’re changing that

Want to operate in China’s biotech scene? Here are five tips

African-Americans are disproportionately enrolled in studies that don’t require informed consent

Denied ‘life-extending opportunities’: Black patients are being left out of clinical trials amid wave of new cancer therapies

With big-name backing, a startup launches to match cancer patients with clinical trials

Stock, sky-high salaries and a $10,000 watch: Startups desperately compete for top experts in gene and cell therapy

Powerful people in health care are finding a new landing pad: Google

Up and down the ladder: The latest comings and goings

DNA donors must demand stronger protection for genetic privacy

Diversity in the biopharma industry makes dollars and sense

Researchers mine emergency contacts to discover genetic clues to disease

The growth of Mass. biotechs is outpacing the number of qualified workers

More female leaders will help drive innovation in the medtech and biotech industries

Cancer centers sell out science when they advertise clinical trials as treatment

Up and down the ladder: The latest comings and goings

How a society gala was used to sell young-blood transfusions to baby boomers desperate to cheat death

Blockchains and health care: promising and moving quickly, though no silver bullet

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day